These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 16061458)

  • 1. Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?
    Zimmermann C; Seccareccia D; Booth CM; Cottrell W
    J Pain Palliat Care Pharmacother; 2005; 19(2):25-31. PubMed ID: 16061458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors.
    Benítez-Rosario MA; Salinas-Martín A; Aguirre-Jaime A; Pérez-Méndez L; Feria M
    J Pain Symptom Manage; 2009 Jun; 37(6):1061-8. PubMed ID: 19171458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent subcutaneous methadone administration in the management of cancer pain.
    Centeno C; Vara F
    J Pain Palliat Care Pharmacother; 2005; 19(2):7-12. PubMed ID: 16061456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.
    Bruera E; Pereira J; Watanabe S; Belzile M; Kuehn N; Hanson J
    Cancer; 1996 Aug; 78(4):852-7. PubMed ID: 8756381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of methadone in the management of pain in cancer patients.
    Bruera E; Neumann CM
    Oncology (Williston Park); 1999 Sep; 13(9):1275-82; discussion 1285-8, 1291. PubMed ID: 10509323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
    Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
    J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved opioid analgesic effect following opioid dose reduction.
    Vorobeychik Y; Chen L; Bush MC; Mao J
    Pain Med; 2008 Sep; 9(6):724-7. PubMed ID: 18816332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphine to methadone conversion: an interpretation of published data.
    Pollock AB; Tegeler ML; Morgan V; Baumrucker SJ
    Am J Hosp Palliat Care; 2011 Mar; 28(2):135-40. PubMed ID: 20555039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid switching between transdermal fentanyl and methadone in cancer patients.
    Mercadante S; Ferrera P; Villari P; Casuccio A
    J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid switch in palliative care, opioid choice by clinical need and opioid availability.
    Müller-Busch HC; Lindena G; Tietze K; Woskanjan S
    Eur J Pain; 2005 Oct; 9(5):571-9. PubMed ID: 16139186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone.
    Thomas Z; Bruera E
    J Pain Symptom Manage; 1995 May; 10(4):315-7. PubMed ID: 7541438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study.
    Lawlor PG; Turner KS; Hanson J; Bruera ED
    Cancer; 1998 Mar; 82(6):1167-73. PubMed ID: 9506365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treating hospitalized children in severe pain with oral methadone].
    Shir Y; Shvelzon V; Rosen G
    Harefuah; 1998 Mar; 134(6):438-41, 503. PubMed ID: 10909571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of hydromorphone-induced neurotoxicity and hyperalgesia.
    Chung KS; Carson S; Glassman D; Vadivelu N
    Conn Med; 2004 Oct; 68(9):547-9. PubMed ID: 15532435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myoclonus associated with high-dose parenteral methadone.
    Ito S; Liao S
    J Palliat Med; 2008 Jul; 11(6):838-41. PubMed ID: 18715174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose ratios between high dose oral morphine or equivalents and oral methadone.
    Chatham MS; Dodds Ashley ES; Svengsouk JS; Juba KM
    J Palliat Med; 2013 Aug; 16(8):947-50. PubMed ID: 23662952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methadone: does stigma play a role as a barrier to treatment of chronic pain?
    Shah S; Diwan S
    Pain Physician; 2010; 13(3):289-93. PubMed ID: 20495594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.